Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) ("Telo" or the "Company"), a leader in diagnostic and prognostic innovation through its proprietary multi-factor telomere analytics, today announced ...
Expanded methodology provides comprehensive quality assessment for both post-acute rehabilitation and long-term care needs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback